XBiotech Announces First Patient Enrolled Into The French National Cancer Institute Sponsored Phase I/II/III Clinical Study For Natrunix Therapy For Colorectal Cancer
XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.
